AP
RARE icon

AHL Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

AHL Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,696
Closed -$404K – 1165
2016
Q3 		$404K Buy
+5,696
New +$364K 0.02% 887

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AHL Partners's RARE Position: Q4 2016 in Review

AHL Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2016, closing a stake of 5,696 shares — an estimated $404K sold.

AHL Partners first reported a position in RARE in Q3 2016 and held it in 1 quarter. The position peaked at $404K in Q3 2016. 174 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

  • AHL Partners reported no remaining Ultragenyx Pharmaceutical position as of Q4 2016 after selling out during the quarter.
  • AHL Partners sold 5,696 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $404K.
  • AHL Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 1 quarter.
  • AHL Partners's Ultragenyx Pharmaceutical position peaked at $404K in Q3 2016.
  • 174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on AHL Partners's 13F filing for Q4 2016, filed 14 Feb 2017.